碳酸酐酶Ⅸ、DLL4的表达与胃腺癌术后复发的相关性研究

Association between carbonic anhydrase Ⅸ,DLL4 expression in gastric adenocarcinoma and recurrence after operation

目的探讨碳酸酐酶Ⅸ (CAⅨ)、DLL4在胃腺癌组织中的表达水平与胃腺癌临床病理特征、肿瘤复发间的关系。方法采用免疫组织化学法检测83例胃腺癌及40例癌旁正常组织中CAⅨ、DLL4、VEGF、CD34的表达程度,回顾性分析83例胃腺癌的临床病理和预后资料。结果胃腺癌组织中CAⅨ和DLL4的阳性表达率均高于癌旁正常组织,差异有统计学意义(P <0.05)。CAⅨ、DLL4的表达程度与肿瘤分化程度、TNM分期、Lauren分型有关(P <0.05),两者与胃腺癌患者的性别、年龄无关(P> 0.05);CAⅨ与DLL4、VEGF、CD34均存在相关性,DLL4与VEGF、CD34存在相关性。生存分析显示,CAⅨ、DLL4高表达与无复发生存时间缩短相关。多因素Cox回归模型分析表明,CAⅨ、DLL4、TNM分期是影响胃腺癌患者术后生存的危险因素。结论 CAⅨ和DLL4胃腺癌中高表达,可能参与胃腺癌的发生和发展,有望成为胃腺癌术后复发的预测因子。

Objective To investigate into the expression of carbonic anhydraseⅨ(CAⅨ)and DLL4 in gastric adenocarcinoma and explore the correlation of their expression levels with clinicopathological parameters and prognosis.Methods Immunohistochemiscal staining was used to detect the levels of CAⅨ,DLL4,VEGF,CD34 in 83 cases of gastric adenocarcinoma and 40 normal tissues adjacent to cancer.Clinicopathological and prognostic data of 83 patients with gastric adenocarcinoma were analyzed retrospectively.Results The positive rates of expression of CAⅨand DLL4 were significantly higher in gastric adenocarcinoma tissues than in normal tissues adjacent to cancer(P<0.05).The expression level of CAⅨand DLL4 was positively correlated with the degree of tumor differentiation,TNM stage and Lauren type(P<0.05).CAⅨand DLL4 expression levels were not related to age or sex(P>0.05).There was a correlation between CAⅨand DLL4,VEGF,CD34 expression.DLL4 also had a correlation with VEGF,CD34 expression.The univariate survival analysis showed that the high expression levels of CAⅨand DLL4 were associated with a shorter time to recurrence.Multivariate Cox regression analysis showed that CAⅨ,DLL4 and TNM stages were risk factors for survival of patients with gastric adenocarcinoma after operation.Conclusion CAⅨand DLL4 are highly expressed in gastric adenocarcinoma and may contribute to the occurrence and development of gastric adenocarcinoma,CAⅨand DLL4 may be a predictor for the recurrence of gastric cancer.